Tirzepatide Research Video Explainer

For in-vitro and laboratory research use only. Not for human or veterinary use. Nothing on this page is medical advice.

This short video explains Tirzepatide as a research compound. Tirzepatide is dual GIP & GLP-1 Incretin Receptor Co-Agonist. It covers its molecular identity (CAS 2023788-19-2, 4813.45 g/mol) and the pathways studied in laboratory models.

In stock and UK lab tested

Key facts

What Tirzepatide is studied for

• Examining synergistic GIP-receptor and GLP-1-receptor dual co-agonism in islet & adipose assays.
• Investigating biased cAMP signalling vs beta-arrestin recruitment at the GLP-1 receptor.
• Studying insulin sensitivity, adipocyte lipid buffering & incretin receptor desensitisation.

What the video covers

Each slide in the 60-second explainer follows one line of published laboratory work, not a medical outcome.

• 1. Imbalanced Dual GPCR Binding Binds GIPR with native affinity and GLP-1R with biased cAMP-favouring affinity.
• 2. Low Beta-Arrestin Recruitment Minimises receptor internalisation while sustaining intracellular cAMP elevation.
• 3. Synergistic Incretin Signalling Enhances beta-cell GSIS and adipocyte metabolic gene transcription in pre-clinical models.

Related research videos

• Retatrutide research video
• Semaglutide research video
• Cagrilintide research video
• All 164 peptide research videos

Batch checks and handling

Every vial carries a report number. Match it to its certificate on the COA verification page before you start work. Lyophilised vials are best kept sealed, dry and at −20 °C or colder, away from light. Reconstitution and storage are covered step by step in our reconstitution and storage guide.

Corex Vitality™ supplies Tirzepatide strictly for in-vitro laboratory research by adults aged 18 or over. It is not a medicine, it is not for human or veterinary use, and no information on this page describes use in people or animals. Read the full terms of sale.